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Abstract
Introduction: The aim was to assess associations among PCOS and NAFLD, the lipoprotein lipase polymorphism gene, and metabolic 
disorders in PCOS.
Material and methods: In 184 women with PCOS and 125 healthy, premenopausal volunteers, sex steroids, lipids, glucose, insulin, ami-
notransferases, free androgen index (FAI), HOMA-IR and E2/T were calculated. Hepatic steatosis was determined by ultrasound. Whole 
genomic DNA was isolated from blood leucocytes. Lipoprotein lipase polymorphisms rs268 and rs328 were analysed by polymerase chain 
reaction (PCR) and minisequencing. 
Results: 57.6% of PCOS women had NAFLD, while women without PCOS had NAFLD in 49.6%. PCOS-NAFLD women had higher BMI, 
WHR and waist circumference compared to women with PCOS without NAFLD and women without PCOS. PCOS-NAFLD women had 
lower SHBG, E2/T ratio, and higher FAI compared to other groups. ALT levels were higher in PCOS women with NAFLD compared to 
other groups. PCOS women with and without NAFLD had higher fasting glucose and insulin and HOMA compared to women without 
PCOS. Women with PCOS had higher triglycerides and lower HDL-C compared to women without PCOS. There was no evidence that 
evaluated polymorphisms influenced hepatic steatosis in women with and without PCOS.
Conclusions: PCOS is not an independent factor influencing NAFLD in women. The influences on NAFLD incidence in women are BMI 
> 25 kg/m², glucose level > 80 mg/dL, E2/T < 80 and ALT > 19 IU/L as independent factors. Hyperandrogenism in PCOS may increase the 
risk of NAFLD indirectly by obesity, insulin resistance, and directly by the hepatotoxic effect. Polymorphisms rs328 and rs268 of the lipo-
protein lipase gene do not affect the occurrence of NAFLD in women with PCOS or without PCOS.  (Endokrynol Pol 2014; 65 (6): 416–421)
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Streszczenie
Wstęp: Celem pracy było zbadanie zależności między zespołem wielotorbielowatych jajników (PCOS) a niealkokoholowym stłuszczniem 
wątroby (NAFLD), polimorfizmem genu lipazy lipoproteinowej oraz zaburzeniami metabolicznymi obserwowanymi w PCOS. 
Materiał i metody: W grupie 184 kobiet z PCOS i wśród 125 zdrowych kobiet premenopauzalnych badano w surowicy stężenia hormonów 
płciowych, frakcji lipidowych, glukozy insuliny i transaminaz oraz obliczano wskaźniki wolnych androgenów (FAI), insulinooporności 
HOMA i E2/T. Stłuszczenie wątroby oceniano ultrasonograficznie. Genomowe DNA izolowano z leukocytów krwi obwodowej metodami 
standardowymi. Do oznaczanie polimorfizmów rs268 i rs 328 lipazy lipoproteinowej użyto metody PCR i minisekwencjonowania. 
Wyniki: częstość występowania NAFLD u kobiet z PCOS nie różniła się istotnie w porównaniu do kobiet bez PCOS. Kobiety z PCOS i 
NAFLD miały istotnie wyższy BMI , WHR i obwód talii w porównaniu z kobietami z PCOS bez NAFLD oraz kobiet bez PCOS. Ponadto 
stwierdzono u nich istotnie niższe SHBG, E2/T i wyższy FAI w porównaniu z kobietami z pozostałych grup. Stężenia transaminazy ala-
ninowej (ALT) w grupie PCOS z NAFLD były istotnie wyższe niż w pozostałych grupach. U kobiet z PCOS z i bez NAFLD obserwowano 
istotnie wyższe stężenia glukozy, insuliny i wskaźnika HOMA w porównaniu z kobietami bez PCOS. Nie stwierdzono istotnych różnic 
w występowaniu określonych polimorfizmów genu lipazy lipoproteinowej w badanych grupach. 
Wnioski: Zespół wielotorbielowatych jajników nie jest niezależnym czynnikiem wpływającym na NAFLD u kobiet. Niezależnymi 
czynnikami mającymi wpływ na wystąpienie NAFLD są: BMI > 25 kg/m², stężenie glukozy > 80 mg/dl, E2/T < 80 oraz ALT > 19 IU/l. 
Hiperandrogenizm w PCOS może pośrednio zwiększać ryzyko NAFLD przez insulinooporność i otyłość oraz bezpośrednio przez efekt 
hepatotoksyczny. Polimorfizmy rs320 i rs268 genu lipazy lipoproteinowej nie mają wpływu na częstość występowania NAFLD u kobiet 
z PCOS. (Endokrynol Pol 2014; 65 (6): 416–421)
Słowa kluczowe: niealkoholowe stłuszczenie wątroby; zespół wielotorbielowatych jajników; polimorfizm genu lipazy lipoproteinowej
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ism and polycystic ovaries. Ultrasound criteria used 
for diagnosis of PCO are the following: presence of 
12 or more follicles in each ovary measuring 2–9 mm in 
diameter and/or increased ovarian volume (> 10 mL). 
Oligo- or amenorrhea was present in all PCOS women. 
All women had normal hepatic and renal functions. 
Their prolactin levels were within normal ranges and 
thyroid function was normal. An overnight dexa-
methasone suppression test (1 mg) and follicular phase 
serum 17-hydroxyprogesterone determination were 
performed to exclude Cushing’s syndrome and the 
late-onset form of congenital adrenal hyperplasia.
The control group consisted of 125 healthy, premen-
opausal volunteers (mean age 27.7 ± 7) with regular 
menses and ultrasonographically normal ovaries. 
Exclusion criteria for the study group and controls 
were: pregnancy, current or previous (within six 
months) use of oral contraceptives, anti-androgens 
or other hormonal drugs, known cardiovascular dis-
ease (CVD), diabetes mellitus, hypertension, cigarette 
smoking, history of liver diseases, and chronic alcohol 
consumption. 
Protocol of the study
We calculated waist-to-hip ratio (WHR) as the quotient 
of waist and hip circumferences and body mass index 
(BMI) as body weight (kg) divided by square of body 
height (m). All subjects underwent abdominal and 
transvaginal ultrasonography. Ultrasound examination 
of liver steatosis was performed by a single examiner 
using a Toshiba APLIO 500 equipped with a 2–5 MHz 
convex array probe and 7–13 MHz linear array probe. 
Scans were performed after a fasting period of at least 
6 h. According to established diagnostic criteria [15], 
the degree of fatty infiltration of the liver was classified 
as mild (hepatic steatosis grade 1), moderate (hepatic 
steatosis grade 2), or severe (hepatic steatosis grade 3). 
Biochemical parameters were measured in all women 
in the morning subsequent to an overnight fast, in 
control and study groups. Plasma was removed and 
stored at –20°C until analysed. Plasma total cholesterol 
(TC), triglycerides (TG), HDL cholesterol (HDL-C) and 
LDL cholesterol (LDL-C), glucose (G), lutropin (LH), 
follicle-stimulating hormone (FSH), total testosterone 
(T), sex hormone binding globulin (SHBG), C-reactive 
protein (CRP), aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) levels were examined in 
all PCOS patients and the control group of women. In 
all women, peripheral insulin sensitivity was estimated 
using fasting insulin levels and homeostasis model 
assessment (HOMA) with the following validated for-
mula: HOMA = [(I0) × (G0)/405] where I0 it is fasting 
insulin (IN µU/mL) and G0 is fasting glucose (in mg/dL). 
Index of free androgens (FAI) was calculated as: [total 
Introduction
Polycystic ovary syndrome (PCOS) is one of the most 
common endocrine disorders among women of repro-
ductive age, and affects 5–10% of this population [1–3]. 
Hyperandrogenism/hirsutism, oligo- or amenorrhea, 
and polycystic ovaries are the features of this syndrome, 
and at least two of the three symptoms listed above are 
required to recognise PCOS [4, 5]. About 50% of PCOS 
women are overweight or obese, with body fat mostly 
centrally located. Insulin resistance, dyslipidemia, risk 
for developing type 2 diabetes and hypertension with 
a subsequent risk of cardiovascular disease are very fre-
quent, even in lean PCOS women [1–3]. Nonalcoholic 
fatty liver disease (NAFLD) is one of the most important 
hepatic manifestations of metabolic disturbances with 
a spectrum from hepatic steatosis, inflammation, fibrosis 
to hepatocellular carcinoma [6, 7]. Women with PCOS 
were recently reported to have a higher prevalence 
of NAFLD than women without this syndrome. The 
reasons were primarily considered to be related to the 
higher prevalence of obesity, dyslipidemia and insulin 
resistance in this population of women [8, 9]. However, 
it has been reported that PCOS itself still accounts for 
the higher risk of NAFLD and abnormal aminotrans-
ferase activity after consideration of the confounding 
effect of obesity [10]. The occurrence of NAFLD may 
also be influenced by lipoprotein lipase (LPL) activity, 
related inter alia to its genetic polymorphism. Several 
described LPL gene polymorphisms are associated with 
a higher incidence of insulin resistance and cardio-
vascular risk factors, but others could exert protective 
effects [11–14]. 
The aim of this study was to determine whether 
there is an association between PCOS and NAFLD, 
and whether in women with PCOS LPL gene poly-
morphism is associated with the aetiology of metabolic 
disorders occurring in these women.
Material and methods
184 obese and overweight (BMI > 25 kg/m2) women 
(mean age 25.3 ± 6) affected by PCOS were enrolled 
in our study. The study protocol was approved by 
the Ethics Committee for Human Studies of Wroclaw 
Medical University. Informed written consent was ob-
tained from all subjects after explanation of the nature, 
purpose and potential risks of the study.
PCOS was defined according to the Rotterdam 
criteria [4], when at least two of the following features 
were present after exclusion of other aetiologies: oligo- 
or anovulation (fewer than six menstrual periods in 
the preceding year), clinical (Ferriman-Gallwey score 
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testosterone ×100]/SHBG. Blood glucose was meas-
ured by the colorimetric method with the Dimension 
laboratory system (Dade Behring Ltd., England). Total 
cholesterol, HDL-C and triglycerides were measured by 
commercial enzymatic methods (BioMerieux, France). 
LDL-C was calculated using Friedewald’s formula. 
Plasma LH, FSH, E2, T, SHBG, and insulin levels were 
measured by chemiluminescent enzyme immunoassays 
(Immulite 2000, DPC, USA). CRP was measured with 
a high sensitive immunonephelometry method using 
CardioPhase hsCRP reagent with the BN laboratory 
system (Dade Behring Marburg GmbH, Germany). 
Whole genomic DNA was isolated from blood leu-
cocytes using Blood Mini Kit produced by Macherey 
Nagel. LPL genotyping was performed by polymerase 
chain reaction (PCR) and minisequencing (Table I). 
In order to amplify fragments of the LPL gene, we 
used a mix containing: 1x PCR buffer, 1.5 mM MgCl2 , 
200 M dATP, 200 M dCTP, 200 M dGTP, 200 M dTTP, 1x Q 
solution, 2x polymerase units (TaKaRa), 200 ng genomic 
DNA, water up to 20 l and primers:
 The DNA was denatured at 95°C for three minutes 
followed by 35 cycles of denaturation at 95°C for 30 
seconds, annealing at 55°C for 30 seconds, and exten-
sion at 72°C for 60 seconds. Amplified fragments were 
purified from oligonucleotides and free dNTPs by SAP 
and ExoI treatment (Fermentas).
The minisequencing method was based on the 
incorporation of single fluorescence-labelled dide-
oxynucleotides to the 3’ end of oligonucleotide which 
was correctly paired to the specific template DNA 
fragment using a SNaPshot kit (Applied Biosystems). 
The SNaPshot reaction was carried out using oligo-
nucleotides:
 — rs268: TTTTTTTTTCAATCTGGGCTATGAGATCA
 — rs328: TTTTTTTTTTTTTTTTTTCAAGTCTCT-
GAATAAGAAGT
 — designed so that it ended immediately before the 
polymorphic sides. The SNaPshot reaction consisted 
of 25 cycles: denaturation at 96°C for ten seconds, 
annealing at 50°C for five seconds, and extension at 
60°C for 30 seconds. 
Products were analysed by an ABI 3100 sequencer 
(Applied Biosystems) and alleles were calculated using 
GeneMapper 4.0.
Statistical analysis
The results obtained were statistically analysed. For 
all groups studied, the number of cases (N), the mean 
(X), median (M), range (min-max), lower and upper 
quartile (25q-75q) and standard deviation (SD) of the 
continuous parameters were calculated. The verification 
of the hypothesis of equality of means of individual 
samples was performed by ANOVA or for groups with 
heterogeneous variance or a small number of cases 
of non-parametric rank sum test, Kruskal-Wallis test 
(homogeneity of variance was checked by Bartlett’s 
test) — marked *. P ≤ 0.05 was considered statistically 
significant, and 0.05 < p < 0.1 was taken as the possibil-
ity of a trend. Statistical analysis was performed using 
the statistical software packages Computer EPIINFO 
Ver. 3.5.2 (dated 17-12-2010). The analysis of multivari-
ate (logistic regression) due to the presence of NAFLD 
among both groups (n = 309, 141 without NAFLD and 
168 with NAFLD) was performed. For the analysis 
introduced: BMI 25 kg/m², waist circumference 84cm, 
WHR 0.8, testosterone 0.5ng/mL, SHBG 34nmol/L, FAI 
5.5, E2/T 80, AST20 U/L, ALT19 U/L, LDL –C 112 mg/dL, 
HDL –C 55 mg/dL, TG 89 mg/dL, CRP 1.1 mg/L, glu-
cose 85 mg/dL, insulin 5.5 µIU/L , HOMA 1.1, PCOS. 
Multivariate analysis was performed by using logistic 
regression (estimation quasi-Newton). P £ 0.05 was 
considered statistically significant,
Results
Women with PCOS and NAFLD had significantly 
higher BMI, WHR and waist circumference compared 
to women with PCOS without NAFLD and women 
without PCOS. In the group of women with PCOS and 
NAFLD, there was also observed significantly lower 
SHBG and lower value E2/T ratio, and a significantly 
higher FAI compared to the other groups (Table II). 
AST concentrations in the investigated groups of women 
were not significantly different, while ALT levels were 
significantly higher in PCOS women with NAFLD 
compared to women with PCOS without NAFLD and 
women without PCOS. Women with PCOS both with 
and without NAFLD had significantly higher levels of fast-
ing glucose and fasting insulin and HOMA compared to 
women without PCOS. Among women with PCOS there 
Table I. Primers' sequences used to LPL gene amplification
Tabela I. Sekwencja starterów wykorzystanych do amplifikacji fragmentów genu LPL
Polymorphism Forward PCR primer (5’-3’) Reverse PCR primer (5’-3’) Fragment size [bp]
rs268 ACG AGC GCT CCA TTC ATC TC CAG TCT CCA GCC TAC CTT TG 230
rs328 TGG CCT GAG TGT GAC AGT TA GAG GAA TGC ATG AAG CTG CC 330
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were significantly higher triglycerides and lower HDL-C 
compared to women without this disease. The values of 
the parameters are shown in Table III. Logistic regression 
showed that all of the analysed factors influence NAFLD, 
but BMI > 25 kg/m2, E2/T < 80, ALT > 19 U/L, glucose 
> 85 mg/dL were independent factors (χ²4 = 182,5, 
p = 0.00000) as shown in Table IV. PCOS influenced 
NAFLD but was not an independent factor.
The studied groups were evaluated for lipoprotein 
lipase gene polymorphisms rs328 and rs268. There 
was no evidence that the evaluated polymorphisms 
influenced hepatic steatosis in PCOS women or in the 
group of women without PCOS. Comparing rs268 
polymorphism, it was found that women with PCOS 
and NAFLD and without NAFLD AA genotype had 
a significantly lower frequency compared to women 
without PCOS. The test results are shown in Table V.
Discussion
Women with PCOS are well known to have a higher 
prevalence of obesity, insulin resistance and dyslipidemia, 
which are common risk factors for NAFLD and metabolic 
syndrome. Therefore they have also been reported to 
have a higher prevalence of NAFLD [10, 16, 17]. Our 
data confirms the prevalence of obesity in PCOS women, 
especially in women with PCOS and NAFLD. Performed 
multivariate analysis showed that body mass index 
Table II. Clinical and biochemical characteristics of PCOS women  — subgroups with (1) and without non alcoholic fatty liver 
disease NAFLD (2) and women without PCOS with NAFLD (3)
Tabela II. Charakterystyka kliniczna i biochemiczna kobiet z PCOS — podgrupa (1) z niealkoholowym stłuszczeniem wątroby, 
bez NAFLD (2) oraz  kobiety bez PCOS z NAFLD (3)
PCOS women  
with NAFLD (1)
PCOS women  
without NAFLD (2)
NAFLD controls (3)*
N = 106 N = 76 N = 62
M IQ uQ p M IQ uQ M IQ uQ 1 vs. 3 2 vs. 3
WHR 0.83 0.78 0.91 *** 0.781 0.749 0.853 0.789 0.745 0.862 *** ns
WC [cm] 88.0 77.0 102.0 *** 76.0 71.0 85.8 79.5 72.0 4.0 * *
Testosterone 
[ng/mL]
0.58 0.43 0.82 ns 0.52 0.35 0.68 0.386 0.260 0.510 *** ***
SHBG [nmol/L] 28.5 18.6 44.4 *** 38.0 25.0 60.8 39.9 29.3 60.4 *** ns
FAI 7.25 4.49 11.22 *** 5.28 2.80 8.00 3.02 1.98 5.39 *** **
*p < 0.05; ** p < 0.001; *** p < 0.0001; ns — not significant; BMI — body mass index; WHR — waist-to-hip ratio; WC — waist circumference; SHBG — sex 
hormone binding globulin; FAI — free androgen index; data is presented as M (median) and lower quartile (lQ) and upper quartile (uQ)
Table III. Biochemical characteristics of PCOS women — subgroups with (1) and without non alcoholic fatty liver disease 
NAFLD (2) and women without PCOS with NAFLD (3)
Tabela III. Charakterystyka biochemiczna kobiet z PCOS — podgrupa (1) z niealkoholowym stłuszczeniem wątroby, bez 
NAFLD (2) oraz kobiety bez PCOS z NAFLD (3)
PCOS women  
with NAFLD (1)
PCOS women  
without NAFLD (2)
NAFLD controls (3)*
N = 106 N = 76 N = 62
M IQ uQ p M IQ uQ M IQ uQ 1 vs. 3 2 vs. 3
ALT[IU/L] 21 15.0 36.0 *** 16.0 13.0 22.0 18.0 13.0 24.0 ** ns
AST[IU/L] 21 17.0 27.0 ns 20.0 17.0 24.0 20.0 16.0 23.0 ** ns
fGlucose[mg/dL] 86.5 81.5 92.0 *** 81.0 78.0 86.0 75.6 75.0 87.0 *** ns
fInsulin[mIU/mL] 6.28 2.64 13.7 ** 4.14 2.00 8.79 2.89 2.00 7.65 ** ns
HOMA-IR 1.24 0.50 3.02 ** 0.78 0.41 1.98 0.50 0.41 1.56 * ns
HDL-chol[mg/dL] 52.0 40.5 65.5 *** 62.0 49.0 74.0 65.5 47.0 86.0 *** ns
Triglyceride[mg/dL] 120.0 67.0 152.5 ** 75.7 57.0 101.0 69.5 53.0 94.0 *** ns
*p < 0.05, ** p < 0.001; *** p < 0.0001; ns — not significant; ALT — alanine aminotransferase; AST — aspartate aminotransferase; f Glucose — fasting glucose; f Insulin 
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> 25 mg/m² is an independent factor influencing NAFLD 
in women. Our results do not confirm the observation of 
other authors that NAFLD in women with PCOS is more 
frequent than in women without PCOS. The prevalence 
of NAFLD in PCOS women ranges from 30 to 60% [18, 
19]. Among our patients with PCOS, 57% had NAFLD, 
but in healthy controls NAFLD was observed in 49%. In 
the whole group with NAFLD, (n = 168) there were 106 
PCOS women and 72 women without PCOS; in the group 
without NAFLD (n = 141), 78 had PCOS and 63 were 
healthy controls. NAFLD was more frequent in PCOS 
women but the difference was statistically not significant 
(p = 0.204).
In the present study, we found that women with 
PCOS and NAFLD had significantly higher levels of ALT 
and FAI and significantly lower E2/T ratio than PCOS 
women without NAFLD and healthy controls. ALT is 
a sensitive indicator of liver cell injury and levels of ALT 
are sensitive in the detection of NAFLD in obese and 
non-obese patients [20, 21]. However, ALT levels can be 
normal in patients with clinical or histological manifesta-
tions of NAFLD [22, 23]. There have been recent sugges-
tions that the upper limit of normal for serum ALT needs 
to be lowered from 40 U/L to 30 U/L for men and 19 U/L 
for women [24]. The levels of ALT in our patients were 
within the normal laboratory range, although in PCOS 
women with NAFLD they were significantly higher 
than in PCOS without NAFLD and in controls. Our data 
shows that ALT > 19 U/L is an independent factor in-
fluencing NAFLD. The androgen excess in women with 
PCOS might contribute to the aggravation of obesity-
related liver cell injury. It is known that women with 
PCOS have greater BMI than controls and that elevated 
ALT exists in both obese and non-obese PCOS women 
[22]. Our data confirms these observations. Chen et al. 
observed that elevated level of ALT in relation to the 
presence of PCOS was independent of the effects of age, 
obesity, high triglycerides, high plasma glucose and LDL 
levels and was positively associated with androgen level. 
In our study, PCOS women with NAFLD had sig-
nificantly higher FAI and lower E2/T ratio than PCOS 
women without NAFLD and than controls. Hyperan-
drogenemia in PCOS may be one of the most important 
factors for elevation of ALT, due to steatosis but also due 
to a direct hepatotoxic effect of androgens unrelated to 
NAFLD. It is known that hyperandrogenism is associ-
ated with the polycystic ovary morphology in women 
with PCOS and can influence the development of meta-
bolic syndrome, dyslipidemia and insulin resistance 
independent of obesity in this group of women [9, 25]. 
The results of our study show E2/T ratio < 80 to be an 
independent factor of NAFLD. We also observed that 
the women with PCOS with NAFLD had significantly 
higher fasting glucose, fasting insulin levels and HOMA 
index than PCOS women without NAFLD and women 
without PCOS. Our results suggest that a fasting glu-
cose level > 85 mg/dL could be an independent factor 
influencing NAFLD. Taken together, these findings sup-
port the suggestion that hyperandrogenism influences 
the metabolic features in PCOS. 
Table V. Genotype and allelic frequencies of rs268 lipoprotein lipase gene polymorphisms
Tabela V. Genotyp i częstość alleli polimorfizmu rs268 genu lipazy lipoproteinowej












Allele frequency 14A/126G 0.0440 22A/82G 0.0311 5A/79G 0.121
rs268-AA 2 (85%) 8 (15.38%) 0 (0.00%)
rs268-AG 10 (14.28%) 6 (11.53%) 6 (14.29%)
rs268-GG 58 (2.85%) 38 (73.08%) 36 (85.71%)
Table IV. Independent factors influencing nonalcoholic fatty liver disease in multivariate analysis (logistic regression)
Tabela IV. Niezależne czynniki wpływające na wystąpienie niealkoholowego stłuszczenia wątroby na podstawie analizy 
wieloczynnikowej
Estimate p OR –95% CI +95% CI
BMI > 25 kg/m² 1.08 0.00007 2.94 1.74 4.98
E2/T -0.593 0.0274 0.553 0.327 0.936
ALT > 19 U/L 0.526 0.0471 1.69 1.01 2.85
f Glucose > 85 mg/dL 0.534 0.0326 1.74 1.05 2.89
P < 0.05 statistically significant; OR — odds ratio; CI — confidence interval; ALT — alanine aminotransferase; f Glucose — fasting glucose; BMI — body mass index
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PCOS, one might say, is an ovarian manifestation 
of metabolic syndrome.
Hepatic lipase is required for the normal metabolism 
of LDL, and there is increasing evidence that genetic 
variation in hepatic lipase activity leads to variation 
of the plasma concentrations of some apolipoprotein 
B containing-lipoproteins, and in the physiochemical 
properties of LDL. To date, most studies of hepatic li-
pase polymorphism have focused on normolipidemic 
individuals [26, 27].
Occurrence of LPL polymorphisms depends on the 
type and the study population. The incidence of rs328 
polymorphism ranges from 9.6 to 20% of the total popula-
tion, while in people with heart disease it is significantly 
lower at 3%. This polymorphism increases LPL activ-
ity, modifying the lipid metabolism and leading to an 
increase in HDL-C, and lower TG and LDL-C [27]. In 
our studies, we found no association of polymorphism 
rs328 LPL with NAFLD in women with and without 
PCOS. Polymorphism rs268 encourages the formation 
of lipid disorders, which occur significantly more often 
in patients with reduced HDL-C and elevated TG. Con-
version of two amino acids has a significant impact on 
the activity of LPL, lowering it. When TG grows by 20%, 
HDL-C decreases by 0.8 mmol/L and the risk of heart 
disease increases 1.4 times [28]. For this polymorphism, 
we found no significant difference among the subjects. 
We observed only significantly less frequent allele AA 
of rs268 polymorphism in women with PCOS with and 
without NAFLD compared to the women without PCOS. 
Unfortunately, these observations do not allow us to draw 
conclusions — whether, for example, is it associated with 
hyperandrogenism — due to the relatively small group 
size, and it needs further investigation. 
Conclusions
PCOS is not an independent factor influencing 
NAFLD in women. The influences on NAFLD incidence 
in women are BMI > 25kg/m², glucose level > 80 mg/dL, 
E2/T < 80 and ALT > 19IU/L as independent factors. 
It is probable that hyperandrogenism in PCOS may 
increase the risk of NAFLD indirectly by obesity, in-
sulin resistance, and directly by the hepatotoxic effect. 
Polymorphisms rs328 and rs268 of the lipoprotein lipase 
gene do not affect the occurrence of NAFLD in women 
with PCOS or without PCOS.
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